| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial.
|
Ann Surg Oncol
|
2006
|
2.69
|
|
2
|
Inflammatory breast cancer: the disease, the biology, the treatment.
|
CA Cancer J Clin
|
2010
|
2.45
|
|
3
|
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision.
|
J Clin Oncol
|
2012
|
2.40
|
|
4
|
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy.
|
Ann Surg Oncol
|
2006
|
2.23
|
|
5
|
Reduced incidence of breast cancer-related lymphedema following mastectomy and breast reconstruction versus mastectomy alone.
|
Plast Reconstr Surg
|
2012
|
2.13
|
|
6
|
Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial.
|
Ann Surg Oncol
|
2011
|
1.93
|
|
7
|
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
|
Clin Cancer Res
|
2012
|
1.90
|
|
8
|
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
|
Cancer
|
2010
|
1.90
|
|
9
|
Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.
|
Cancer
|
2010
|
1.79
|
|
10
|
A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer.
|
Cancer
|
2009
|
1.76
|
|
11
|
Lymph node ratio predicts disease-specific survival in melanoma patients.
|
Cancer
|
2009
|
1.63
|
|
12
|
Factors influencing career choice among medical students interested in surgery.
|
Curr Surg
|
2004
|
1.53
|
|
13
|
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.
|
Clin Cancer Res
|
2009
|
1.48
|
|
14
|
COX-2 overexpression increases motility and invasion of breast cancer cells.
|
Int J Oncol
|
2005
|
1.45
|
|
15
|
Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients.
|
Ann Surg Oncol
|
2010
|
1.45
|
|
16
|
Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy.
|
Plast Reconstr Surg
|
2011
|
1.42
|
|
17
|
Inflammatory breast cancer: what we know and what we need to learn.
|
Oncologist
|
2012
|
1.41
|
|
18
|
Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.
|
Int J Cancer
|
2011
|
1.39
|
|
19
|
Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee.
|
Cancer
|
2006
|
1.36
|
|
20
|
A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer.
|
J Surg Res
|
2008
|
1.33
|
|
21
|
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
|
Clin Cancer Res
|
2013
|
1.30
|
|
22
|
American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns.
|
Ann Surg Oncol
|
2012
|
1.29
|
|
23
|
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer.
|
Breast Cancer Res Treat
|
2008
|
1.28
|
|
24
|
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.
|
Oncologist
|
2011
|
1.22
|
|
25
|
Brief intervention by surgeons can influence students toward a career in surgery.
|
J Surg Res
|
2003
|
1.22
|
|
26
|
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer.
|
Breast Cancer Res Treat
|
2010
|
1.19
|
|
27
|
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype.
|
Eur J Cancer
|
2011
|
1.19
|
|
28
|
Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis.
|
Cancer
|
2010
|
1.19
|
|
29
|
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results.
|
Clin Breast Cancer
|
2003
|
1.18
|
|
30
|
Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients.
|
Ann Surg Oncol
|
2010
|
1.16
|
|
31
|
Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
|
Cancer
|
2011
|
1.14
|
|
32
|
Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery.
|
Am J Surg
|
2009
|
1.13
|
|
33
|
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast.
|
Cancer
|
2010
|
1.11
|
|
34
|
Melanoma adrenal metastasis: natural history and surgical management.
|
Am J Surg
|
2008
|
1.10
|
|
35
|
How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?
|
Cancer
|
2008
|
1.10
|
|
36
|
Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons.
|
Ann Surg Oncol
|
2012
|
1.09
|
|
37
|
Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death.
|
Ann Surg Oncol
|
2011
|
1.08
|
|
38
|
Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells.
|
J Surg Res
|
2008
|
1.07
|
|
39
|
Potential targets to encourage a surgical career.
|
J Am Coll Surg
|
2005
|
1.06
|
|
40
|
Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer.
|
J Surg Res
|
2006
|
1.06
|
|
41
|
A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group.
|
J Am Coll Surg
|
2004
|
1.05
|
|
42
|
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning.
|
Ann Surg
|
2011
|
1.05
|
|
43
|
Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer.
|
Ann Surg
|
2006
|
1.03
|
|
44
|
Biology, treatment, and outcome in very young and older women with DCIS.
|
Ann Surg Oncol
|
2012
|
1.02
|
|
45
|
Does blue dye contribute to success of sentinel node mapping for breast cancer?
|
Ann Surg Oncol
|
2010
|
0.99
|
|
46
|
Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.
|
Ann Surg Oncol
|
2009
|
0.99
|
|
47
|
Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.98
|
|
48
|
Role of cyclooxygenase-2 in breast cancer.
|
J Surg Res
|
2002
|
0.97
|
|
49
|
Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.
|
Cancer
|
2010
|
0.95
|
|
50
|
COX-2 induces IL-11 production in human breast cancer cells.
|
J Surg Res
|
2006
|
0.95
|
|
51
|
Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells.
|
Mol Cancer
|
2010
|
0.95
|
|
52
|
Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer.
|
Am J Surg
|
2008
|
0.94
|
|
53
|
Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy.
|
Cancer
|
2010
|
0.94
|
|
54
|
Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin).
|
Breast J
|
2007
|
0.93
|
|
55
|
Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.
|
Clin Cancer Res
|
2011
|
0.93
|
|
56
|
Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy.
|
Ann Surg Oncol
|
2010
|
0.92
|
|
57
|
Selection of metastatic breast cancer cells based on adaptability of their metabolic state.
|
PLoS One
|
2012
|
0.92
|
|
58
|
Role of COX-2 in tumorospheres derived from a breast cancer cell line.
|
J Surg Res
|
2010
|
0.91
|
|
59
|
Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer.
|
Cancer
|
2011
|
0.91
|
|
60
|
Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer.
|
Clin Exp Metastasis
|
2010
|
0.90
|
|
61
|
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
|
Breast Cancer Res Treat
|
2015
|
0.90
|
|
62
|
Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311).
|
World J Surg Oncol
|
2008
|
0.90
|
|
63
|
Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center.
|
Am J Surg
|
2006
|
0.89
|
|
64
|
Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells.
|
J Surg Res
|
2007
|
0.89
|
|
65
|
Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.88
|
|
66
|
The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy.
|
Cancer
|
2006
|
0.87
|
|
67
|
Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted?
|
Ann Surg Oncol
|
2013
|
0.86
|
|
68
|
Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma.
|
Springerplus
|
2013
|
0.85
|
|
69
|
Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
|
Surgery
|
2005
|
0.85
|
|
70
|
Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.
|
Melanoma Res
|
2012
|
0.84
|
|
71
|
Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer.
|
Cancer Med
|
2013
|
0.84
|
|
72
|
Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?
|
Expert Rev Anticancer Ther
|
2007
|
0.83
|
|
73
|
Atypical dermatofibrosarcoma protuberans in the breast.
|
Breast J
|
2005
|
0.82
|
|
74
|
Circulating tumor cells in non-metastatic triple-negative breast cancer.
|
Breast Cancer Res Treat
|
2014
|
0.82
|
|
75
|
Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy.
|
Am J Clin Oncol
|
2015
|
0.82
|
|
76
|
Improved postoperative pain control using thoracic paravertebral block for breast operations.
|
Breast J
|
2009
|
0.81
|
|
77
|
Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome.
|
Breast J
|
2010
|
0.81
|
|
78
|
Oncoplastics: techniques for reconstruction of partial breast defects based on tumor location.
|
J Surg Oncol
|
2011
|
0.81
|
|
79
|
Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines.
|
J Surg Res
|
2010
|
0.80
|
|
80
|
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass.
|
Breast Cancer Res Treat
|
2012
|
0.80
|
|
81
|
Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma.
|
Melanoma Res
|
2013
|
0.80
|
|
82
|
Giant pelvic schwannoma with ancient change.
|
J Am Coll Surg
|
2003
|
0.79
|
|
83
|
Invasive lobular carcinoma predicts micrometastasis in breast cancer.
|
J Surg Res
|
2012
|
0.79
|
|
84
|
Orthopedic surgery implications of breast cancer.
|
Expert Rev Anticancer Ther
|
2008
|
0.78
|
|
85
|
The relationship between blood IL-12p40 level and melanoma progression.
|
Int J Cancer
|
2014
|
0.78
|
|
86
|
Assessment of Practice Patterns Following Publication of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Therapy in Stage I and II Invasive Breast Cancer.
|
Ann Surg Oncol
|
2015
|
0.78
|
|
87
|
Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow.
|
Cancer Biol Ther
|
2011
|
0.77
|
|
88
|
Surgical treatment of pregnancy associated breast cancer.
|
Breast Dis
|
2006
|
0.77
|
|
89
|
Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node.
|
Am J Surg
|
2005
|
0.77
|
|
90
|
Mastectomy performed with scissors following tumescent solution injection.
|
J Surg Oncol
|
2003
|
0.77
|
|
91
|
Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation.
|
Ann Surg
|
2017
|
0.76
|
|
92
|
Detection of circulating melanoma cells in the blood of melanoma patients: a preliminary study.
|
Melanoma Res
|
2015
|
0.76
|
|
93
|
Lymphoscintigraphy does not enhance sentinel node identification or alter management of patients with early breast cancer.
|
Curr Surg
|
2006
|
0.76
|
|
94
|
Re: Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer, by van Rijk MC, Tanis PJ, Nieweg OE, et al.
|
J Surg Oncol
|
2006
|
0.75
|
|
95
|
A gene signature in breast cancer.
|
N Engl J Med
|
2007
|
0.75
|
|
96
|
How heterogeneous cell populations, cancer cell dormancy, and minimal residual disease influence the natural history of cancers.
|
Oncology (Williston Park)
|
2011
|
0.75
|
|
97
|
Emerging patterns of practice in the implementation and application of sentinel lymph node biopsy in breast cancer patients in the United States.
|
J Surg Oncol
|
2003
|
0.75
|
|
98
|
Is axillary dissection needed when the sentinel node is positive? No: it is time to rethink axillary lymph node dissection when the sentinel node is positive.
|
J Surg Oncol
|
2008
|
0.75
|
|
99
|
Relapse of thrombotic thrombocytopenic purpura associated with decreased VWF cleaving activity.
|
Am J Med Sci
|
2002
|
0.75
|
|
100
|
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
|
Ann Surg
|
2017
|
0.75
|
|
101
|
The suture scaffold technique for improved cosmesis in partial mastectomy defects.
|
J Surg Oncol
|
2010
|
0.75
|
|
102
|
Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
|
Breast Cancer Res Treat
|
2015
|
0.75
|
|
103
|
Intramammary lymph node presenting as the primary breast mass in infiltrating lobular carcinoma.
|
Curr Surg
|
2006
|
0.75
|